The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Acute Respiratory Distress Syndrome (ARDS) Market Expected To Reach Based On Its 2026 Value?
The market size for acute respiratory distress syndrome (ards) has experienced significant expansion in recent years. It is anticipated to grow from $1.41 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. The historical growth can be attributed to several factors including an increasing occurrence of respiratory infections, the expansion of hospital ICU infrastructure, greater understanding of ards management protocols, the constrained availability of advanced ventilation devices, and the widespread adoption of supportive care practices.
The market for acute respiratory distress syndrome (ards) is expected to experience substantial expansion over the next few years. It is projected to achieve a size of $2.42 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This anticipated growth during the forecast period is fueled by factors such as technological progress in mechanical ventilation and ECMO systems, increased research and development in ARDS therapeutics, the global expansion of critical care units, rising investments in personalized patient management solutions, and the growing incidence of severe pneumonia and sepsis. Significant trends for the forecast period include the increasing adoption of mechanical ventilation and ECMO devices, a rise in the prevalence of ARDS due to COVID-19 and other respiratory illnesses, the expanding use of advanced diagnostic tests for early detection, the growth of critical care and ICU facilities, and a focus on personalized and supportive care management.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Affecting The Acute Respiratory Distress Syndrome (ARDS) Market Demand?
The growing incidence of respiratory illnesses is anticipated to propel the acute respiratory distress syndrome (ARDS) market forward. Respiratory illness encompasses a range of medical conditions affecting the respiratory system, including airways and lungs, which can lead to breathing difficulties. The escalating number of respiratory illnesses, exemplified by conditions such as COVID-19, is a primary catalyst driving the expansion of the acute respiratory distress syndrome (ARDS) market. As more individuals develop these illnesses, the demand for ARDS treatments and therapies is expected to rise, thereby stimulating market growth. For instance, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, Australia registered a total of 474 asthma-related deaths, comprising 325 females and 149 males. This total is almost identical to the 473 asthma-related deaths reported in 2022, indicating a consistent trend in asthma mortality over these two years. Consequently, the increasing prevalence of respiratory illnesses is a significant driver for the growth of the acute respiratory distress syndrome (ARDS) market.
How Is The Acute Respiratory Distress Syndrome (ARDS) Market Segmented Across Different Segment Categories?
The acute respiratory distress syndrome (ards) market covered in this report is segmented –
1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care
What Trends Are Influencing Changes In The Acute Respiratory Distress Syndrome (ARDS) Market?
Companies at the forefront of the acute respiratory distress syndrome market are concentrating on developing advanced immune modulators to boost patient survival and decrease inflammation. Immune modulators are treatments designed to restore immune equilibrium by targeting dysfunctional inflammatory pathways without suppressing the body’s overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage company, obtained FDA Fast Track designation for its primary product, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy functions by restocking gelsolin, a crucial immune regulatory protein, to modulate NLRP3 inflammasome activation, improve microbial clearance, remove toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently being evaluated in a 600-patient global Phase 2b trial for moderate to severe ARDS and may also become available through the FDA Expanded Access or Compassionate Use program. The Fast Track designation allows for accelerated regulatory interactions, a rolling review of marketing applications, and eligibility for priority review, potentially speeding up its market entry and providing a new therapeutic choice for patients with restricted alternatives.
Which Organizations Play A Role In The Acute Respiratory Distress Syndrome (ARDS) Market Landscape?
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy
Get The Full Acute Respiratory Distress Syndrome (ARDS) Market Report:
Where Is The Acute Respiratory Distress Syndrome (ARDS) Market Primarily Concentrated By Region?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Acute Respiratory Distress Syndrome (ARDS) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Acute Respiratory Distress Syndrome (ARDS) Market 2026, By The Business Research Company
Acute Coronary Syndrome Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report
Severe Acute Respiratory Syndrome Treatment Market Report 2026
Respiratory Disease Testing Market Report 2026
https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model